178 related articles for article (PubMed ID: 7700905)
1. Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Benyunes MC; Thompson JA; York A; Buckner CD; Fefer A
Prog Clin Biol Res; 1994; 389():229-38. PubMed ID: 7700905
[No Abstract] [Full Text] [Related]
2. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.
Fefer A; Benyunes MC; Massumoto C; Higuchi C; York A; Buckner CD; Thompson JA
Semin Oncol; 1993 Dec; 20(6 Suppl 9):41-5. PubMed ID: 8284691
[No Abstract] [Full Text] [Related]
3. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.
Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA
Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
6. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
7. Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies.
Klingemann HG
Leuk Lymphoma; 1992 Dec; 8(6):421-9. PubMed ID: 1284296
[TBL] [Abstract][Full Text] [Related]
8. [The role of interleukin-2--based immunotherapy in hematological malignancies].
Ackerstein A; Toren A; Slavin S; Nagler A
Harefuah; 1996 May; 130(9):613-7. PubMed ID: 8794642
[No Abstract] [Full Text] [Related]
9. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
10. Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.
Blaise D; Stoppa AM; Olive D; Brandely M; Tiberghien P; Attal M; Attal J; Reiffers J; Demeocq F; Pico JL
Bone Marrow Transplant; 1991; 7 Suppl 2():146. PubMed ID: 1878687
[No Abstract] [Full Text] [Related]
11. Interleukin-2 in bone marrow transplantation.
Verma UN; Charak BS; Rajagopal C; Mazumder A
Cancer Treat Res; 1995; 76():315-36. PubMed ID: 7577342
[No Abstract] [Full Text] [Related]
12. Interleukin-2 in autologous bone marrow transplantation.
Charak BS
Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow purging with LAK cells.
Giuliodori L; Moretti L; Stramigioli S; Luchetti F; Annibali GM; Baldi A
Int J Artif Organs; 1993 Dec; 16 Suppl 5():108-10. PubMed ID: 8013966
[TBL] [Abstract][Full Text] [Related]
14. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
[No Abstract] [Full Text] [Related]
15. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).
Slavin S; Or R; Kapelushnik Y; Drakos P; Ackerstein A; Vourka-Karussis U; Weiss L; Nagler A
Leukemia; 1992 Nov; 6 Suppl 4():164-6. PubMed ID: 1434823
[TBL] [Abstract][Full Text] [Related]
17. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
[No Abstract] [Full Text] [Related]
18. Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
Malkovska V; Sondel PM
J Natl Cancer Inst Monogr; 1990; (10):69-72. PubMed ID: 2189478
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
Benyunes MC; Massumoto C; York A; Higuchi CM; Buckner CD; Thompson JA; Petersen FB; Fefer A
Bone Marrow Transplant; 1993 Aug; 12(2):159-63. PubMed ID: 8401364
[TBL] [Abstract][Full Text] [Related]
20. Autologous bone marrow transplantation in haematologic malignancies.
Marmont AM; Carella AM
Haematologica; 1986; 71(1):1-12. PubMed ID: 3084348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
